Seller record · Telehealth service

Noom

By Peptide Alliance, Editorial publisherRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: Each mention describes selected pharmacy partners without naming a facility. The terms, transparency, privacy and program surfaces carry it. 2 more criteria also fail; see the table below.

At a glance

NoomTelehealth service

5/8criteria passed

Price: From $149 for the first three weeks
Sells: compounded semaglutide, compounded tirzepatide, and 3 more
FDA letters: None on file

Visit Noom See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A weight-management subscription whose medical arm prescribes generic, compounded and brand GLP-1 drugs. It publishes an explanation of what a certificate of analysis is and supplies one only on request.

Operating entity Noom, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Noom's GLP-1 access and transparency page
S2	Prescription gating	PASS	Noom's dosingpreference page
S3	Pharmacy identification	FAIL	Noom's GLP-1 access and transparency page
S4	Compounding disclosure	FAIL	Noom's GLP-1 access and transparency page
S5	Analytical documentation	FAIL	Noom's GLP-1 access and transparency page
S6	Business address	PASS	Noom's terms and conditions of use page
S7	Price disclosure	PASS	Noom's website
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSThe transparency page names Dr. Jeffrey Egler, MD as a double board-certified physician in family medicine and lifestyle medicine, alongside two named pharmacists.Source: Noom's GLP-1 access and transparency page.

S2PASSTwo clinical survey screens asking dosing and medication preference come before any payment field.Source: Noom's dosingpreference page.

S3FAILEach mention describes selected pharmacy partners without naming a facility. The terms, transparency, privacy and program surfaces carry it.Source: Noom's GLP-1 access and transparency page.

S4FAILThe transparency page states that generic, compounded and brand medications are prescribed, and no page states that a compounded product lacks Food and Drug Administration approval.Source: Noom's GLP-1 access and transparency page.

S5FAILThe transparency page defines a certificate of analysis and states that patients may request one from their care coordination team, so no document is reachable from the site.Source: Noom's GLP-1 access and transparency page.

S6PASSThe terms print a street address with a suite number at One Palmer Square in Princeton, New Jersey, given for written notice.Source: Noom's terms and conditions of use page.

S7PASSThe homepage prints an initial three-week subscription with four weeks of medication from 149 dollars, then 349 dollars per month for the twelve-week subscription after it, and a second tier at 79 dollars then 199 dollars.Source: Noom's website.

S8PASSNo FDA warning letter names the entity, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, brand GLP-1 prescriptions, metformin, behavioral weight-management coaching.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit Noom

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.